Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis

OBJECTIVE: To investigate whether blood–brain barrier (BBB) permeability, as measured by dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI), can provide early detection of suboptimal treatment response in relapsing–remitting multiple sclerosis (RRMS). METHODS: Thirty‐five RRMS patients s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cramer, Stig P., Simonsen, Helle J., Varatharaj, Aravinthan, Galea, Ian, Frederiksen, Jette L., Larsson, Henrik B. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032831/
https://www.ncbi.nlm.nih.gov/pubmed/29604233
http://dx.doi.org/10.1002/ana.25219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032831/
https://www.ncbi.nlm.nih.gov/pubmed/29604233
http://dx.doi.org/10.1002/ana.25219

Ejemplares similares